Back to catalogue
BSFA

Bsf Enterprise PLC

Health Care First-pass screen £3.30m
240/1000 Overall fit
AI beneficiary 35% 15
Operating leverage 25% 32
Valuation 25% 30
Downside protection 15% 22

First-pass take

Pre-revenue biotech with zero AI strategy or exposure; tissue engineering (lab-grown leather, cultivated meat additives, corneal repair) is orthogonal to AI spending thesis. Loss-making (£1.0m net loss); going concern warning flagged despite £15m fundraise planned Feb 2026.

Flags

loss-makinggoing-concernpre-revenuemicro-capcapital-dependentbiotech-clinical-riskno-valuation-datacash-burnm-and-a-spin-out-strategy